Mount Sinai Researchers Discover Treatment Option for Rare Genetic Disorder
August 5, 2020
Rare Daily Staff
Researchers at the Icahn School of Medicine, who used a novel genetic sequencing technology to diagnose and treat an 18-year old girl who had suffered from a severe autoimmune condition since infancy, said their discovery serves as a model of personalized diagnosis and treatment for patients with genetic diseases.
The technology, tailored to the patient’s own genetic code at a single cell level, helped the researchers characterize an unknown mutation in a gene called JAK1 that caused the patient’s immune system to be permanently turned on, resulting in rashes over much of her skin, growth abnormalities, kidney failure, allergic hypersensitivities, and an unusual inflammatory condition throughout the digestive tract.
Dusan Bogunovic, associate professor of microbiology and pediatrics at the Icahn School of Medicine at Mount Sinai, and a faculty member of The Mindich Child Health and Development Institute, led the study published in the August 3 issue of the journal Immunity.
“This research helps better understand the basic function of JAK1, which has broad implications for diseases of the immune system and how to treat them. In addition, the genetic discoveries uncovered in this case open up new research avenues into the complexities of how genetic diseases manifest and present a model of the future of personalized medicine,” said Bogunovic, who is also a faculty member at the Precision Immunology Institute at Mount Sinai, and director of the Center for Inborn Errors of Immunity. “By coupling advanced clinical care with next-generation sequencing and detailed laboratory studies, we successfully diagnosed and treated a life-threatening disease.”
Autoinflammatory diseases are caused by abnormal activation of the immune system, leading to recurrent episodes of inflammation that may result in damaged or failed organs. The researchers determined that not all of the patient’s cells carried this mutation and had different genetic makeups or genotypes, what the researcher describe as a mosaic.
“Most genes use both their maternal and paternal copies, called alleles,” said Bogunovic. “Our findings show the JAK1 mutation in this patient used only one copy per cell, known as monoallelic expression. This challenges the textbook principles of genetics and may help explain irregularities that are frequently encountered across genetic diseases.”
In the paper, the researchers describe the use of next-generation genomic, molecular, and multi-parametric immunological tools to probe the effects of the patient’s JAK1 mutation. By mapping the genotype of JAK1 across the patient’s body, researchers were able to pinpoint precisely when the mutation arose in early development in the embryo. It later gave way to a host of symptoms from early childhood to early adulthood. The hunt began for a specific therapy that would curb the excessive activity of her mutant JAK1 and potentially cure her inflammatory symptoms.
“We identified one drug, tofacitinib, a JAK inhibitor, that curbed the excessive activity of her hyperactive inflammation,” said Bogunovic. “When administered the therapy, she rapidly improved within weeks. Her skin lesions cleared, her daily gastrointestinal symptoms resolved, and the clinical signs of inflammation went away, putting the patient in remission for two years until her unfortunate demise from coronavirus-related illness.”
Photo: Dusan Bogunovic, associate professor of microbiology and pediatrics at the Icahn School of Medicine at Mount Sinai
Sign up for updates straight to your inbox.